TG Therapeutics to Host Conference Call on Third Quarter 2026 Financial Results and Business Update

What happened

TG Therapeutics said it will hold a conference call on November 9, 2026, at 8:30 a.m. Eastern Time to discuss third-quarter 2026 results and its business outlook for the rest of the year. Chief Executive Michael S. Weiss will host; results will be released before the call.

Confirmed

Global impact / market context

The call is a scheduled point for investors to hear the company’s reported results and outlook. Any updates on sales, costs, or plans could shape expectations for future cash available and spending, but the announcement itself contains no financial results or new business guidance.

Analyst inference

TG Therapeutics describes itself as a commercial-stage biotechnology company focused on B-cell diseases and says it has FDA approval for BRIUMVI to treat adults with relapsing forms of multiple sclerosis. The upcoming results may give investors information about its business, but none is provided here.

Confirmed

What to watch

1. The company says it will issue a press release with its third-quarter financial results before the November 9 call; those reported figures may clarify recent business performance. Confirmed
2. Listen for the outlook for the remainder of 2026, which management says it will discuss; any specific targets or changes are not stated in this announcement. Confirmed
3. Investors could focus on any discussion of BRIUMVI and the research pipeline, since updates on products or development plans could affect expectations for revenue and spending. Analyst inference

Evidence

• Original source link unavailable